BR112018013421A2 - métodos e composições para tratar a síndrome de hunter - Google Patents

métodos e composições para tratar a síndrome de hunter

Info

Publication number
BR112018013421A2
BR112018013421A2 BR112018013421A BR112018013421A BR112018013421A2 BR 112018013421 A2 BR112018013421 A2 BR 112018013421A2 BR 112018013421 A BR112018013421 A BR 112018013421A BR 112018013421 A BR112018013421 A BR 112018013421A BR 112018013421 A2 BR112018013421 A2 BR 112018013421A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
syndrome
hunter
present
Prior art date
Application number
BR112018013421A
Other languages
English (en)
Inventor
Lee Byoung-Ju
Byun Han-Yeul
Jang In-Young
Seo Jin-Wook
Lee Kyuhyun
Jin Thong-Gyu
OKUYAMA Torayuki
Kim Yong-Chul
Original Assignee
Green Cross Corp
Medigenebio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp, Medigenebio Corp filed Critical Green Cross Corp
Publication of BR112018013421A2 publication Critical patent/BR112018013421A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção proporciona, entre outras coisas, composições e méto-dos para entrega no snc de idursulfase-beta, uma proteína iduronato-2-sulfatase recombinante humana, para o tratamento eficaz da síndrome de hunter. as composi-ções e métodos proporcionados pela presente invenção reduzem eficazmente os sintomas não apenas no cérebro e na medula espinal, mas também nos tecidos peri-féricos, incluindo coração, fígado, baço, pulmão e rim.
BR112018013421A 2015-12-30 2016-12-21 métodos e composições para tratar a síndrome de hunter BR112018013421A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562272843P 2015-12-30 2015-12-30
US201662369970P 2016-08-02 2016-08-02
PCT/KR2016/015060 WO2017116066A1 (en) 2015-12-30 2016-12-21 Methods and compositions for treating hunter syndrome

Publications (1)

Publication Number Publication Date
BR112018013421A2 true BR112018013421A2 (pt) 2018-12-18

Family

ID=59224844

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013421A BR112018013421A2 (pt) 2015-12-30 2016-12-21 métodos e composições para tratar a síndrome de hunter

Country Status (19)

Country Link
US (1) US11052135B2 (pt)
EP (1) EP3397270B1 (pt)
JP (2) JP2019504053A (pt)
KR (2) KR20180090387A (pt)
CN (1) CN108430494A (pt)
BR (1) BR112018013421A2 (pt)
CL (1) CL2018001782A1 (pt)
CO (1) CO2018007251A2 (pt)
DK (1) DK3397270T3 (pt)
EA (1) EA201891533A1 (pt)
FI (1) FI3397270T3 (pt)
HK (1) HK1258054A1 (pt)
MX (1) MX2018008029A (pt)
MY (1) MY193846A (pt)
PE (1) PE20181329A1 (pt)
PH (1) PH12018550102A1 (pt)
SG (1) SG11201805598WA (pt)
UA (1) UA123704C2 (pt)
WO (1) WO2017116066A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
CN112236164A (zh) * 2018-05-30 2021-01-15 株式会社医用基因生物 用于通过侧脑室施用治疗亨特综合征的方法和组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
IL291554B2 (en) * 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
PL2588130T3 (pl) 2010-06-25 2017-09-29 Shire Human Genetic Therapies, Inc. Dostarczanie środków terapeutycznych do OUN
JP6045492B2 (ja) * 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
BR112013020195B1 (pt) 2011-02-11 2020-01-07 Swedish Orphan Biovitrum Ab (Publ) Composição farmacêutica livre de citrato compreendendo anakinra e uso de anakinra
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
EA201792099A1 (ru) 2011-12-23 2018-05-31 Шир Хьюман Дженетик Терапис, Инк. Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы
US9603908B2 (en) * 2012-03-30 2017-03-28 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate-2-sulfatase

Also Published As

Publication number Publication date
CN108430494A (zh) 2018-08-21
US11052135B2 (en) 2021-07-06
EP3397270A4 (en) 2019-09-18
MX2018008029A (es) 2018-08-23
KR102272399B1 (ko) 2021-07-05
KR20180090387A (ko) 2018-08-10
FI3397270T3 (fi) 2024-05-10
UA123704C2 (uk) 2021-05-19
MY193846A (en) 2022-10-28
EA201891533A1 (ru) 2018-12-28
CL2018001782A1 (es) 2018-11-09
EP3397270B1 (en) 2024-04-17
SG11201805598WA (en) 2018-07-30
EP3397270A1 (en) 2018-11-07
JP6987924B2 (ja) 2022-01-05
KR20200099621A (ko) 2020-08-24
JP2019504053A (ja) 2019-02-14
HK1258054A1 (zh) 2019-11-01
JP2020147578A (ja) 2020-09-17
CO2018007251A2 (es) 2018-07-19
PH12018550102A1 (en) 2019-02-11
PE20181329A1 (es) 2018-08-20
US20200268857A1 (en) 2020-08-27
DK3397270T3 (da) 2024-05-06
WO2017116066A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
MX2020001513A (es) Agentes de union a clec9a y su uso.
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
WO2015044292A8 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
MX347471B (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
PH12017500032A1 (en) Improved a� protofibril binding antibodies
EP3818991A3 (en) Compositions and methods for treating diseases
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
WO2017103094A3 (en) Means and methods for treating copper-related diseases
EA201691567A1 (ru) Способы лечения легких травм головного мозга
BR112017013999A2 (pt) ?composição derivada de uma bifidobactéria?
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112016025481A2 (pt) alimentos, sistemas, métodos e estojos para provisão de substituição de eletrólito
BR112018013421A2 (pt) métodos e composições para tratar a síndrome de hunter
WO2017029558A3 (en) Methods for improving health of farmed fish
EA201792085A1 (ru) Смешанные дисульфидные конъюгаты тиенопиридиновых соединений и их применение
MX2019003725A (es) Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]